Breast cancer brain metastases: biology and new clinical perspectives

Because of improvements in the treatment of patients with metastatic breast cancer, the development of brain metastases (BM) has become a major limitation of life expectancy and quality of life for many breast cancer patients. The improvement of management strategies for BM is thus an important clinical challenge, especially among high-risk patients such as human epidermal growth factor receptor 2-positive and triple-negative patients. However, the formation of BM as a multistep process is thus far poorly understood. To grow in the brain, single tumor cells must pass through the tight blood–brain barrier (BBB). The BBB represents an obstacle for circulating tumor cells entering the brain, but it also plays a protective role against immune cell and toxic agents once metastatic cells have colonized the cerebral compartment. Furthermore, animal studies have shown that, after passing the BBB, the tumor cells not only require close contact with endothelial cells but also interact closely with many different brain residential cells. Thus, in addition to a genetic predisposition of the tumor cells, cellular adaptation processes within the new microenvironment may also determine the ability of a tumor cell to metastasize. In this review, we summarize the biology of breast cancer that has spread into the brain and discuss the implications for current and potential future treatment strategies.

[1]  P. Johnston,et al.  CD44 Potentiates the Adherence of Metastatic Prostate and Breast Cancer Cells to Bone Marrow Endothelial Cells , 2004, Cancer Research.

[2]  A. Twijnstra,et al.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma , 2002, Cancer.

[3]  Thomas S. Reese,et al.  FINE STRUCTURAL LOCALIZATION OF A BLOOD-BRAIN BARRIER TO EXOGENOUS PEROXIDASE , 1967, The Journal of cell biology.

[4]  I. Macdonald,et al.  Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth , 1994, Clinical & Experimental Metastasis.

[5]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[6]  Tae-Hee Lee,et al.  Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability* , 2003, The Journal of Biological Chemistry.

[7]  L. Gras,et al.  REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Bhatia,et al.  The shifting landscape of metastatic breast cancer to the CNS , 2013, Neurosurgical Review.

[9]  A. Stan,et al.  Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer , 2007, Modern Pathology.

[10]  Chiun-Sheng Huang,et al.  Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy , 2015, Clinical Cancer Research.

[11]  V. Kataja,et al.  Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study , 2011, Breast Cancer Research.

[12]  Jamie R. Kutasovic,et al.  Metastatic progression of breast cancer: insights from 50 years of autopsies , 2013, The Journal of pathology.

[13]  B. Felding-Habermann,et al.  Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. , 2010, The American journal of pathology.

[14]  M. Gnant,et al.  Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. , 2014, Breast.

[15]  V. Zagonel,et al.  Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. , 2014, Cancer treatment reviews.

[16]  G. Mills,et al.  Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. , 2010, Neoplasia.

[17]  G. Sauter,et al.  Clinical Relevance of Loss of 11p15 in Primary and Metastatic Breast Cancer: Association with Loss of PRKCDBP Expression in Brain Metastases , 2012, PloS one.

[18]  R. Jandial,et al.  Role of the neural niche in brain metastatic cancer. , 2014, Cancer research.

[19]  E. Gerstner,et al.  Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Solin,et al.  Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. , 2013, Clinical breast cancer.

[21]  Suyun Huang,et al.  Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice , 2004, Clinical & Experimental Metastasis.

[22]  A. Iafrate,et al.  Brain tumor cells in circulation are enriched for mesenchymal gene expression. , 2014, Cancer discovery.

[23]  Z. Ren,et al.  Breast cancer subtypes predispose the site of distant metastases. , 2015, American journal of clinical pathology.

[24]  Stephen T C Wong,et al.  Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis , 2012, Cancer.

[25]  Y. Mo,et al.  Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain , 2013, EMBO molecular medicine.

[26]  I. Wilhelm,et al.  Transmigration of Melanoma Cells through the Blood-Brain Barrier: Role of Endothelial Tight Junctions and Melanoma-Released Serine Proteases , 2011, PloS one.

[27]  M. D. Wetzel,et al.  A Correction to the Research Article Titled: "The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis" by L. Zhang, L. D. Ridgway, , 2013 .

[28]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[29]  Meenakshi Singh,et al.  Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status. , 2004, Archives of pathology & laboratory medicine.

[30]  G. Sauter,et al.  Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients , 2014, Oncotarget.

[31]  Tae-Hee Lee,et al.  Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. , 2004, Molecular cancer research : MCR.

[32]  N. Harbeck,et al.  Management of Patients with Brain Metastases Receiving Trastuzumab Treatment for Metastatic Breast Cancer , 2011, Oncology Research and Treatment.

[33]  O. Chinot,et al.  Recent trends in epidemiology of brain metastases: an overview. , 2012, Anticancer research.

[34]  O. Salazar,et al.  Breast Cancer: Metastatic Patterns and Their Prognosis , 1988, Southern medical journal.

[35]  V. Perry,et al.  Review: Activation patterns of microglia and their identification in the human brain , 2013, Neuropathology and applied neurobiology.

[36]  M. Mehta,et al.  Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. , 2015, Clinical breast cancer.

[37]  Bert Vogelstein,et al.  DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .

[38]  R. Weil,et al.  Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. , 2015, Neuro-oncology.

[39]  M. Kris,et al.  Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis , 2014, Cell.

[40]  L. Ellis,et al.  Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. , 2000, Cancer research.

[41]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[42]  H. Nakshatri,et al.  Angiopoietin‐2 mediates blood–brain barrier impairment and colonization of triple‐negative breast cancer cells in brain , 2014, The Journal of pathology.

[43]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[44]  D. Harder,et al.  Astrocytes Directly Influence Tumor Cell Invasion and Metastasis In Vivo , 2013, PloS one.

[45]  Jochen Herms,et al.  Real-time imaging reveals the single steps of brain metastasis formation , 2010, Nature Medicine.

[46]  I. Fidler,et al.  Metastasis results from preexisting variant cells within a malignant tumor. , 1977, Science.

[47]  P. Steeg,et al.  Notch1 Inhibition Alters the CD44hi/CD24lo Population and Reduces the Formation of Brain Metastases from Breast Cancer , 2011, Molecular Cancer Research.

[48]  A. Vortmeyer,et al.  Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization , 2008, Clinical & Experimental Metastasis.

[49]  Ju-Seog Lee,et al.  Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar. , 2011, The American journal of pathology.

[50]  M. Dank,et al.  First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study. , 2014, Anticancer research.

[51]  C. Swanton,et al.  Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab , 2006, Acta oncologica.

[52]  G. Guler,et al.  EGFR expression and gene copy number in triple-negative breast carcinoma. , 2010, Cancer genetics and cytogenetics.

[53]  K. Blackwell,et al.  Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  Yeu‐Tsu N. Lee,et al.  Breast carcinoma: Pattern of metastasis at autopsy , 1983, Journal of surgical oncology.

[55]  V. Valero,et al.  Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells , 2011, International journal of cancer.

[56]  M. Mehta The dandelion effect: treat the whole lawn or weed selectively? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  J. Price,et al.  Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[58]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  M. Ono,et al.  Disruption of the blood brain barrier by brain metastases of triple‐negative and basal‐type breast cancer but not HER2/neu‐positive breast cancer , 2010, Cancer.

[60]  S. Iacobelli,et al.  Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines , 2015, Oncotarget.

[61]  C. Miller,et al.  Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases , 2011, Breast Cancer Research.

[62]  P. Brastianos,et al.  Human breast cancer metastases to the brain display GABAergic properties in the neural niche , 2014 .

[63]  C. McPherson,et al.  Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases. , 2010, Neuro-Oncology.

[64]  Stephen Fox,et al.  HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer , 2010, Breast Cancer Research.

[65]  M. Preusser,et al.  Breast cancer brain metastases responding to primary systemic therapy with T-DM1 , 2013, Journal of Neuro-Oncology.

[66]  Wei Yin,et al.  The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis , 2013, Science Translational Medicine.

[67]  R. Kerbel,et al.  Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. , 2013, Breast.

[68]  K. Pogoda,et al.  Breast cancer subtypes and response to systemic treatment after whole‐brain radiotherapy in patients with brain metastases , 2010, Cancer.

[69]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[70]  C. Osipo,et al.  Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer , 2014, Front. Oncol..

[71]  H. Iwata,et al.  Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis , 2014, Breast Cancer Research and Treatment.

[72]  Marissa Friedman,et al.  Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets , 2015, Cancers.

[73]  I. Bechmann,et al.  Microglia promote colonization of brain tissue by breast cancer cells in a Wnt‐dependent way , 2010, Glia.

[74]  Mi Hyun Kim,et al.  Activation of Notch Signaling in a Xenograft Model of Brain Metastasis , 2008, Clinical Cancer Research.

[75]  S. Alıcı,et al.  Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology) , 2012, Oncology.

[76]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  M. Speicher,et al.  Cancer: Hematogenous dissemination of glioblastoma multiforme , 2014 .

[78]  Erin M. Olson,et al.  Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  J. Polli,et al.  Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer , 2011, Pharmaceutical Research.

[80]  S. Margolin,et al.  CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  M. Campone,et al.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. , 2013, The Lancet. Oncology.

[82]  K. Watabe,et al.  Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition , 2013, OncoTargets and therapy.

[83]  N. Sibson,et al.  The Vascular Basement Membrane as “Soil” in Brain Metastasis , 2009, PloS one.

[84]  C. Stadelmann,et al.  Carcinoma cells misuse the host tissue damage response to invade the brain , 2013, Glia.

[85]  P. Steeg,et al.  Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer , 2010, Clinical Cancer Research.

[86]  S. Steinberg,et al.  Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. , 2007, Cancer research.

[87]  M. Speicher,et al.  Hematogenous dissemination of glioblastoma multiforme , 2014, Science Translational Medicine.

[88]  K. Pantel,et al.  Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.

[89]  T. Yoneda,et al.  Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44. , 2003, Experimental cell research.

[90]  M. Westphal,et al.  Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. , 2013, The American journal of pathology.